Avecho Biotechnology (AVE) H1 2024 earnings summary

Executive summary

• Revenue declined 30% year-over-year to $312,187, mainly due to lower Vital ET® sales to Ashland.

• Net loss increased 2.2% year-over-year to $2,175,251, driven by higher R&D expenses for the Phase III CBD insomnia trial.

• R&D tax incentive and other income rose 80% to $725,182, reflecting increased R&D activity.

• No dividends were paid or declared for the period.

• The company commenced dosing in its pivotal Phase III clinical trial for a TPM®-enhanced CBD soft-gel capsule targeting insomnia.

Financial highlights

• Revenue from contracts with customers: $312,187 (down 30% year-over-year).

• Gross profit: $207,196 (down from $318,129 year-over-year).

• R&D expenses: $1,945,144 (up 75% year-over-year).

• Administrative expenses: $1,156,895 (down 33% year-over-year).

• Net operating cash outflow: $628,245 (vs. $400,397 outflow prior year).

Outlook and guidance

• The company intends to continue receiving advances on R&D tax incentives to fund ongoing Phase III trial costs.

• Directors believe the company can continue as a going concern, supported by working capital, history of capital raising, and R&D incentives.